Perflow Medical Announces First Clinical Use of the Cascade Net and Acquisition of TailorMed


July 23, 2018—Perflow Medical, an Israel-based medical device company that develops tools for neurovascular interventions, announced the first clinical cases of the Cascade dynamic nonocclusive remodeling net, which is commercially available in Europe. The procedures were performed by Alejandro Tomasselo, MD, who is Head of Interventional Neuroradiology at Hospital Vall d'Hebron in Barcelona, Spain.

According to the company, the Cascade device is a nonocclusive net that is the latest addition the company’s portfolio of neurovascular devices based on Perflow's Cerebral Net technology platform. Cascade provides mechanical support during coil embolization of intracranial aneurysms. Its compliant net allows continuous blood flow in the parent vessel to improve procedural efficiency.

In the company's announcement, Dr. Tomasselo commented, “My clinical experience with the Cascade Net has been very positive. It improved control during the coiling procedure and the braided net design significantly expanded my treatment options. It can help prevent the coils from herniating into the parent vessel, compact the coils during the procedure, and manipulate the coiling microcatheter if needed, all while blood flows freely through the net. I look forward to incorporating the device as part of my clinical practice."

In addition, Perflow Medical announced it has acquired TailorMed, an Israel-based medical technology developer and manufacturer of endovascular products, to support the company's continued commercial expansion.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.